Journal of Diabetes Research / 2012 / Article / Tab 2

Research Article

Angiotensin-Converting Enzyme Genotype and Peripheral Arterial Disease in Diabetic Patients

Table 2

Comparisons of characteristics by insertion/deletion (I/D) polymorphism of angiotensin-converting enzyme genotypes.

CharacteristicsAngiotensin-converting enzyme genotype
IIIDDD

(%)46539288
Age, years64.1 (11.7)62.8 (11.2)63.4 (11.0)
Sex
  Men219 (47.1)192 (49.0)43 (48.9)
 Women246 (52.9)200 (51.0)45 (51.1)
Duration of diabetes, years11.8 (8.2)10.7 (7.9)10.8 (7.6)
Body mass index, kg/m224.8 (3.6)24.8 (3.3)25.0 (3.6)
Smoking
 Never smokers309 (66.6)244 (62.2)58 (65.9)
 Current or former smokers155 (33.4)148 (37.8)30 (34.1)
Hypertension
 No191 (41.1)158 (40.3)37 (42.0)
 Yes274 (58.9)234 (59.7)51 (58.0)
Systolic blood pressure, mmHg135.8 (18.1)133.9 (16.6)135.5 (19.5)
Diastolic blood pressure, mmHg83.3 (9.9)83.2 (9.5)84.3 (10.7)
Hemoglobin , %7.8 (1.8)7.9 (1.9)8.2 (1.9)
Dyslipidemia
 No167 (35.9)132 (33.7)35 (39.8)
 Yes298 (64.1)260 (66.3)53 (60.2)
Total cholesterol, mg/dL204.3 (43.1)208.3 (43.8)199.5 (40.3)
Ln(triglycerides), mg/dL5.0 (0.6)5.0 (0.6)4.9 (0.6)
High-density lipoprotein cholesterol, mg/dL47.4 (13.5)48.9 (13.6)46.7 (12.9)
Low-density lipoprotein cholesterol, mg/dL114.1 (34.7)115.4 (34.2)110.5 (27.6)
Ln[lipoprotein (a)], mg/dL4.7 (1.2)4.7 (1.1)4.6 (1.2)
Uric acid, mg/dL5.2 (2.1)5.3 (1.9)5.3 (2.1)
Peripheral arterial disease
 No430 (92.5)358 (91.3)76 (86.4)
  Yes35 (7.5)34 (8.7)12 (13.6)

Data are expressed as mean (SD) or (percentage).
None of the above comparisons among the genotypes was statistically significant (i.e., all ).

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.